The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

The licensing deal with Biosion involves an experimental treatment for severe asthma and skin disorder known as atopic ...

The study compared the risk and cumulative incidence of requiring glaucoma surgery—such as minimally invasive surgery, ...

As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

17.5% and 22.5% had atopic dermatitis, and 7.6% and 15.8% had facial involvement, respectively (all P <.0001). Occupational CD results in chronic morbidity and is associated with disruptions in ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...